Top Biopharma Deals of 2024: Comprehensive Review and Impact Analysis

In 2024, the top ten biopharma partnerships reached $31 billion in potential value, with cancer therapies dominating six of the ten deals. Despite fewer blockbuster agreements than in 2023, investments in protein drugs and early-stage platforms remain strong, signalling the industry’s appetite for innovation.

Key Highlights:

Protein Drugs & Oncology: Novartis’s $2.89B deal with PeptiDream and $3B partnership with Dren Bio focus on cutting-edge radioligand therapies and bispecific antibodies. Instil Bio’s $2B collaboration with ImmuneOnco Biopharmaceuticals emphasizes bispecifics for solid tumors.

Precision Medicine: Roche’s $2B partnership with MOMA Therapeutics taps into next-generation precision oncology tools targeting challenging enzymes.

Broader Therapeutics: Eli Lilly’s $3.2B acquisition of Morphic advances oral integrin inhibitors, while AstraZeneca’s $2B deal with CSPC drives cardiovascular innovation

With protein therapeutics, cutting-edge platforms, and early-stage R&D driving growth, now is the time to align your brand with these transformative advancements. View the full article here.

Partner with us to elevate your profile, connect with C-suite decision-makers, and explore sponsorship opportunities that position your organization at the forefront of biopharma innovation. Contact us.

About Biopharma Dealmakers

Providing timely information on dealmaking activity, Biopharma Dealmakers brings together life scientists, biotech and pharmaceutical professionals, and investors. Organizations seeking partners from the biopharma and investment community are invited to advertise and publish profile articles. To learn more click here>>

The publication is free to access at Nature.com/biopharmdeal and print issues are distributed to the readers of Nature Biotechnology and Nature Reviews Drug Discovery.